biote Corp.
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
BTMD$1.08-2.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| March 31, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $5,320 | $24,123 |
| Accounts receivable, net | 7,397 | 6,868 |
| Inventory, net | 19,881 | 19,064 |
| Other current assets | 3,758 | 4,615 |
| Total current assets | 36,356 | 54,670 |
| Property and equipment, net | 10,701 | 10,753 |
| Capitalized software, net | 5,074 | 4,525 |
| Goodwill | 5,833 | 5,833 |
| Intangible assets, net | 3,957 | 4,266 |
| Operating lease right-of-use assets | 2,558 | 2,701 |
| Deferred tax assets, net | 24,481 | 24,793 |
| Other non-current assets | 72 | 72 |
| Total assets | $89,032 | $107,613 |
| Liabilities and Stockholders’ Deficit | ||
| Current liabilities: | ||
| Accounts payable | $8,236 | $6,826 |
| Accrued expenses | 10,282 | 9,806 |
| Term loan, current | 6,250 | 6,250 |
| Deferred revenue, current | 2,848 | 3,017 |
| Operating lease liabilities, current | 610 | 592 |
| Share repurchase liabilities | — | 18,500 |
| Total current liabilities | 28,226 | 44,991 |
| Term loan, net of current portion | 94,425 | 95,782 |
| Revolving loans | 5,000 | 5,000 |
| Deferred revenue, net of current portion | 922 | 1,097 |
| Operating lease liabilities, net of current portion | 2,137 | 2,298 |
| Other non-current liability | 124 | 344 |
| TRA liability | 4,190 | 4,386 |
| Earnout liabilities | 1,963 | 4,112 |
| Total liabilities | 136,987 | 158,010 |
| Commitments and contingencies (See Note 18) | ||
| Stockholders’ Deficit | ||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued or outstanding as of March 31, 2026 and December 31, 2025, respectively | — | — |
| Class A common stock, $0.0001 par value; 600,000,000 shares authorized; 31,574,479 and 32,300,867 shares issued, 29,986,979 and 30,713,367 shares outstanding as of March 31, 2026 and December 31, 2025, respectively | 3 | 3 |
| Class V voting stock, $0.0001 par value; 100,000,000 shares authorized; 7,249,879 shares issued, 5,221,653 shares outstanding each as of March 31, 2026 and December 31, 2025, respectively | 1 | 1 |
| Additional paid-in capital | — | — |
| Accumulated deficit | (46,032) | (49,549) |
| Accumulated other comprehensive loss | (27) | (29) |
| Treasury stock, at cost | (10,036) | (8,965) |
| biote Corp.’s stockholders’ deficit | (56,091) | (58,539) |
| Noncontrolling interest | 8,136 | 8,142 |
| Total stockholders’ deficit | (47,955) | (50,397) |
| Total liabilities and stockholders’ deficit | $89,032 | $107,613 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.